Citations

Mayo Clinic

Showing 10 of 108523 citations.

The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder
Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Linder, Brian J , Cameron, Anne P. , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Neurourology and Urodynamics | July 16, 2024 | Volume: 43 | Issue: 8 | Pages: 1742-1752

10.1002/nau.25532 | PMID 39010271 Get It

AbstractPurposeThe purpose of this guideline is to provide evidence‐based guidance to clinicians of all specialties on the evaluation, management, and treatment of idiopathic overactive bladder (OAB). The guideline informs the reader on valid diagnostic processes and provides an approach to selecting treatment options for patients with OAB through the shared decision‐making process, which will maximize symptom control and quality of life, while minimizing adverse events and burden of disease.MethodsAn electronic search employing OVID was used to systematically search the MEDLINE and EMBASE databases, as well as the Cochrane Library, for systematic reviews and primary studies evaluating diagnosis and treatment of OAB from January 2013 to November 2023. Criteria for inclusion and exclusion of studies were based on the Key Questions and the populations, interventions, comparators, outcomes, timing, types of studies and settings (PICOTS) of interest. Following the study selection process, 159 studies were included and were used to inform evidence‐based recommendation statements.ResultsThis guideline produced 33 statements that cover the evaluation and diagnosis of the patient with symptoms suggestive of OAB; the treatment options for patients with OAB, including Noninvasive therapies, pharmacotherapy, minimally invasive therapies, invasive therapies, and indwelling catheters; and the management of patients with BPH and OAB.ConclusionOnce the diagnosis of OAB is made, the clinician and the patient with OAB have a variety of treatment options to choose from and should, through shared decision‐making, formulate a personalized treatment approach taking into account evidence‐based recommendations as well as patient values and preferences.
Characterisation and prognostic impact of ZRSR2 mutations in myeloid neoplasms
Al‐Kali, Aref , Yacout, Mahmoud, Katamesh, Bahga , Jabban, Yazan, He, Rong , Viswanatha, David S., Jevremović, Dragan , Bessonen, Kurt, Palmer, Jeanne , Foran, James M. , Begna, Kebede H. , Patnaik, Mrinal M. , Jevremovic, Dragan , Greipp, Patricia T. , Saliba, Antoine N. , Hefazi, Mehrdad , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

No container title available | July 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4590446/v1 Get It

Abstract The ZRSR2 gene is a member of the spliceosome gene family which are frequently mutated in myeloid neoplasms. ZRSR2 mutations (ZRSR2m) occur in less than 5% of MDS, CMML, and AML. Our study included 164 ZRSR2m patients (98.8% males) and 98 ZRSR2wt MDS control cohort. In the ZRSR2m group, there were 53 MDS (32%), 39 CCUS (24%), 33 MPN (20%), 23 MDS/MPN overlap (14%), 15 AML (9%), and 1 MPAL (0.6%). Most MDS patients were the low blast subtype (n=37, 70%). Twenty-seven MDS patients (51%), and 23 CCUS patients (59%) had absolute monocyte count ≥0.5 x109/L and 18 of 23 MDS/MPN overlap were CMML (78%). Mutations in ZRSR2 were spread across the entire gene. The median number of co-mutations was 2, with TET2 (51%) and ASXL1 (32%) being the most common. U2AF1 and SRSF2, previously described as mutually exclusive with ZRSR2, were found in 10.4% of patients. Median overall survival (OS) was 51 months, and significantly varied among MNs (p=0.004). ZRSR2m MDS patients had better mOS than the MDS control cohort with ZRSR2wt (35 vs 22 months, p=0.013). ZRSR2m patients with isolated TET2 co-mutation and higher hemoglobin showed improved survival, while patients with RUNX1m, higher WBC count showed worse OS.
Assessment of Aminoglycoside-Induced Hearing Loss Risk in the Perinatal Period
Thompson, Whitney S. , Saba, Leslie , Hasadsri, Linda , Girard, Sylvie, Schimmenti, Lisa A. , Bendel‐Stenzel, Ellen , Wick, Myra , Brumbaugh, Jane E. , Schimmenti, Lisa A , Brumbaugh, Jane E , Thompson, Whitney S

American Journal of Perinatology | July 15, 2024 | Volume: 42 | Issue: 01 | Pages: 126-129

10.1055/s-0044-1788335 | PMID 39008985 Get It

Objective This study aimed to determine the prevalence and heteroplasmy level(s) of MT-RNR1 variants m.1555A > G and m.1494C > T, which are associated with aminoglycoside-induced hearing loss, in a general perinatal population. This study also aimed to characterize the association of these variants and their heteroplasmy levels with hearing loss outcomes with and without aminoglycoside exposure. Study Design Droplet digital polymerase chain reaction was performed on 479 maternal DNA samples from a general perinatal biobank at our institution to detect the presence and heteroplasmy levels of MT-RNR1 variants m.1555A > G and m.1494C > T. Testing of paired neonatal specimen(s) was planned for positive maternal tests. A retrospective chart review was performed to characterize the population, identify aminoglycoside exposures, and determine hearing outcomes. Results All maternal samples tested negative for MT-RNR1 variants m.1555A > G and m.1494C > T. Maternal and neonatal subjects had high rates of aminoglycoside exposure (15.9 and 13.9%, respectively). No subjects with sensorineural or mixed hearing loss had documented aminoglycoside exposure. Conclusion This study demonstrated that a larger sample size is needed to establish the prevalence of these variants as no subjects tested positive. Determination of variant prevalence in the neonatal population, association of variant heteroplasmy levels with hearing outcomes, and reliability of maternal testing as a surrogate for neonatal testing are important next steps toward universal prenatal or newborn screening. Key Points
Local Cutaneous Scrotal Involvement of Paratesticular Mesothelioma
Maniam, Ganesh , Gupta, Sounak , Agrawal, Shruti , Tekin, Burak , Nguyen, Giang

The American Journal of Dermatopathology | July 15, 2024 | Volume: 46 | Issue: 10 | Pages: e91-e95

10.1097/dad.0000000000002802 | PMID 39008503 Get It

Abstract: Paratesticular mesothelioma (malignant mesothelioma arising from the tunica vaginalis of the testis) represents a small proportion of mesothelial neoplasms, and cutaneous involvement by paratesticular mesothelioma is very rare. Cutaneous involvement can manifest as scrotal subcutaneous nodules from regional spread, distant metastasis, or direct extension through surgical scars. Mesothelioma has 3 histopathologic classifications that include epithelioid, biphasic, and sarcomatoid, which is rarely seen in paratesticular mesothelioma. Given the rarity of this condition, cutaneous mesothelioma may be misdiagnosed as histologic mimics, such as metastatic adenocarcinoma or adnexal neoplasms; thus, appropriate immunohistochemical workup and clinical correlation are required to make an accurate diagnosis. In this case, a 75-year-old man with a history of paratesticular mesothelioma, status postorchiectomy, presented with right-sided scrotal swelling, erythema, and subcutaneous nodules. These nodules were identified as local recurrence with cutaneous involvement by paratesticular mesothelioma on histopathologic examination. This case highlights the clinical and histopathologic features of this diagnosis and underscores the importance of dermatopathologists being aware of this condition to ensure accurate diagnosis.
Plasma Transfusion and Recipient Outcomes: One Size Does Not Fit All!
Kor, Daryl J. , Görlinger, Klaus , Shander, Aryeh

Anesthesia & Analgesia | July 15, 2024 | Volume: 139 | Issue: 2 | Pages: 251-253

10.1213/ane.0000000000006963 | PMID 39008863 Get It

Autoimmune ‘secondary synaptopathies’: do NMDAR antibodies cause a primary extra-synaptopathy?
Zhao, Meng , Irani, Sarosh R. , Irani, Sarosh R , Zhao, Meng , Lynch, David R.

Brain | July 15, 2024 | Volume: 147 | Issue: 8 | Pages: 2601-2603

10.1093/brain/awae236 | PMID 39073761 Get It

This scientific commentary refers to ‘NMDA receptor autoantibodies primarily impair the extrasynaptic compartment’ by Jamet et al. (https://doi.org/10.1093/brain/awae163).
Dosimetric consequences of flap dose due to rapid beam off control for a high intensity carbon ion radiation therapy synchrotron
Tsubouchi, Toshiro , Nomura, Takuya , Kanai, Tatsuaki, Beltran, Chris , Beltran, Chris J , Furutani, Keith M. , Yagi, Masashi , Shimizu, Shinichi

Medical Physics | July 15, 2024 | Volume: 51 | Issue: 10 | Pages: 7393-7403

10.1002/mp.17309 | PMID 39008830 Get It

AbstractBackgroundIn carbon ion radiation therapy (CIRT) the predominant method of irradiation is raster scanning, called dose driven continuous scanning (DDCS) by Hitachi, allowing for continuous synchrotron extraction. The reduction in irradiation time is highly beneficial in minimizing the impact of patient and target movement on dose distribution. The RF knock out (RFKO) slow‐extraction method is commonly used for beam on/off control. When the Hitachi synchrotron receives a beam off signal the control system stops the RFKO and after some delay time (t‐delay) during which the beam intensity declines, a high‐speed steering magnet (HSST) is used to sweep the remaining beam from isocenter to a beam dump for safety reasons. Mayo Clinic Florida (MCF) will use a very short delay of the HSST operation from the RFKO beam OFF signal to minimize the delay time and delayed dose. MCF clinical beam intensity, a tenfold increase over HIMAK, is still less than 100 mMU/ms (approximately 4.9 × 109 pps for 430 MeV/u).PurposeThe rapid beam off control (RBOC) proposed for MCF is associated with the occurrence of flap dose (FD), which refers to the asymmetric shoulder of the spot dose profile formed from the beam bent by HSST deviating from its planned spot position on the isocenter plane. In this study, we quantitatively assessed FD, proposed a treatment planning system (TPS) implementation using a flap spot (FS) and evaluated its impact on dose distribution.MethodThe experiments were conducted at the Osaka Heavy Ion Therapy Center (HIMAK) varying the t‐delay from 0.01 to 1 ms in a research environment to simulate the MCF RBOC. We studied the dependence of FD position on beam transport and its dependence on energy and beam intensity. FD was generated by delivering 10000 continuous spots on the central axis that are occasionally triggered by an external 10 Hz gate signal. Measurements were conducted using an oscilloscope, and the nozzle's spot position monitor (SPM) and dose monitor (DM).ResultAll spot profile data were corrected for the gain of the SPM's beam intensity dependence. FD was determined by fitting the (SPM) Profile data to a double Gaussian. The position of the FS was found to be transport path dependent, with FS occurring on the opposite sides of the scanning x‐direction for vertical and horizontal ports, respectively, as predicted by transport calculations. It was observed that the FD increases with beam intensity and did not exhibit a significant dependence on energy. The effect of FD on treatment planning is shown to have no significant dose impact on the organs at risk (OARs) near the target for clinical beam intensities and a modest increase for very high intensities.ConclusionUsing HIMAK in research mode the implications are that the FD has no clinical impact on the clinical CIRT beam intensities for MCF and maybe planned for higher intensities by incorporating FS into the TPS to predict the modest increased dose to OARs. A method for commissioning and quality assurance of FD has been proposed.
Specification and de-labelling of unspecified allergic reactions to penicillins at a family medicine clinic
Ton, Angie , Ilges, Dan , Ton, Angie Nu , Ilges, Dan

BMJ Open Quality | July 15, 2024 | Volume: 13 | Issue: 3 | Pages: e002785

10.1136/bmjoq-2024-002785 | PMID 39009463 Get It

Advancing Cardiovascular Health Equity With Artificial Intelligence: A Collective Ethical Responsibility
Adedinsewo, Demilade , Adedinsewo, Demilade A

Circulation | July 15, 2024 | Volume: 150 | Issue: 3 | Pages: 174-176

10.1161/circulationaha.124.068113 | PMID 39008553 Get It

Acute Respiratory Distress Syndrome and the Meaning of Hospital Mortality*
Qadir, Nida , Bauer, Philippe R.

Critical Care Medicine | July 15, 2024 | Volume: 52 | Issue: 8 | Pages: 1319-1321

10.1097/ccm.0000000000006340 | PMID 39007577 Get It